Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ONS 44th Annual Congress /
Emerging uses of PARP inhibitors

11th - 14th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.05.19
Views: 1516

Teresa Knoop - Vanderbilt Ingram Cancer Center, Brentwood, USA

Teresa Knoop speaks to ecancer at ONS 2019 about how the use of PARP inhibitors has changed.

She explains that clinical trials have so far indicated that PARP inhibitors may be more promising in treating breast and ovarian cancers with BRCA gene mutations.

Teresa concludes by saying that more research is needed to discover if PARP inhibitors are useful in treating cancers without known mutations or to discover potential combination strategies.

This programme has been supported by an unrestricted educational grant from Pfizer. 

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation